Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354566 | 1.00 | GAA (0.53) | GAACDK2MEN1KMT2APTGS2 | |
| SCHEMBL623371 | 1.00 | GAA (0.53) | GAACDK2MEN1KMT2APTGS2 | |
| SCHEMBL15315387 | 0.90 | KMT2A (0.50) | GAACDK2MEN1KMT2APTGS2 | |
| SCHEMBL18688530 | 0.89 | KMT2A (0.49) | GAACDK2MEN1KMT2APTGS2 | |
| SCHEMBL13479601 | 0.86 | MAPT (0.47) | GAACDK2MEN1KMT2AMAPT | |
| SCHEMBL22624828 | 0.84 | CDK2 (0.56) | CDK2MEN1KMT2APTGS2MAPT | |
| SCHEMBL10118539 | 0.81 | MEN1 (0.60) | CDK2MEN1KMT2APTGS2MAPT | |
| SCHEMBL15312914 | 0.81 | MEN1 (0.60) | CDK2MEN1KMT2APTGS2MAPT | |
| SCHEMBL15317953 | 0.80 | MAPT (0.54) | GAAMEN1KMT2APTGS2MAPT | |
| SCHEMBL623631 | 0.79 | GAA (0.63) | GAACDK2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | claimed |
| US-20230381152-A1 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | MOONSHOT PHARMA LLC (US) | 2023-11-30 | — | — | US | disclosed |
| EP-4215614-A1 | COMBINATION THERAPY FOR DYSTROPHIN-RELATED DISEASES | Dynacure (FR) | 2023-07-26 | — | — | EP | disclosed |
| US-11654135-B2 | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors | MOONSHOT PHARMA LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11352624-B2 | Reducing nonsense-mediated MRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200283762-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3690048-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10647983-B2 | Reducing nonsense-mediated mRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2020-05-12 | — | — | US | disclosed |
| US-20170159049-A9 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2017-06-08 | — | — | US | disclosed |
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3041958-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194630-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2016-07-07 | — | — | US | disclosed |
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| WO-2015035091-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654135-B2 | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors | CD274, MYD88, PDCD1LG2 | GAA 3526/4885CDK2 2845/4885MEN1 4022/4885 |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | GAA 2293/4885CDK2 960/4885MEN1 3033/4885 |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | GAA 2293/4885CDK2 960/4885MEN1 3033/4885 |
| US-20230381152-A1 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | CD274, MYD88, PDCD1LG2 | GAA 3526/4885CDK2 2845/4885MEN1 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.